kubsv retweeted
$GEO linked to 10 deaths, lawmakers call for contract terminations
EXCLUSIVE: BOMBSHELL ICE INVESTIGATION EXPOSES SUBSTANDARD MEDICAL CARE IN DETAINEE DEATHS, WITH GEO GROUP FACILITIES LINKED TO 10 CASES - SF CHRONICLE
LAWMAKERS CALL FOR CONTRACTOR PENALTIES AND POSSIBLE CONTRACT TERMINATIONS - SF CHRONICLE
$KAZR A tungsten miner with ties to two of President Trump’s sons is preparing to go public, the latest twist for a business that has courted both government funding and Democrats’ scrutiny wsj.com/finance/trump-family… via @WSJ
$NFE New Fortress Energy Inc. (NASDAQ: NFE) today announced that it has agreed to lease ten mobile turbines that can generate up to 300 megawatts of power to a US-based investment-grade company. The lease is for an initial period of five years.
The turbines are expected to be delivered in stages beginning in the fourth quarter of 2026 and finalized in the first quarter of 2027. The transaction is expected to be accretive to NFE’s earnings and enhance its liquidity profile.
455
$INO INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it secured a judgment in its favor, in the amount of $80,416,101, on all claims it filed against defendants VGXI, Inc. ("VGXI") and GeneOne Life Science, Inc. ("GeneOne") in the case captioned INOVIO Pharmaceuticals, Inc. v. VGXI, Inc. and GeneOne Life Science, Inc
513
$VIR $GILD Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors. Vir Biotechnology will be eligible to receive up to $135 million in total upfront and near-term preclinical milestone payments, consisting of $90 million in upfront consideration, which includes $65 million in cash and a $25 million equity investment at a 30% premium, and up to $45 million in potential near-term preclinical milestones. In addition, Vir Biotechnology has the potential to receive up to $1.74 billion in further development, regulatory and commercial milestones, along with tiered high single-digit to low double-digit royalties on net sales.
4
299
$AUUD Since the original record date, Auddia has experienced a significant expansion in strategic momentum, driven primarily by the emergence of LT350, a subsidiary of Thramann Holdings that would become a subsidiary of MCFN upon closing of the proposed merger. LT350 is developing a patented distributed datacenter platform designed to meet rapidly growing AI inference demand. LT350’s architecture deploys datacenter grade GPU infrastructure in the airspace of existing parking lots, a structural advantage that directly addresses the community resistance bottlenecks slowing datacenter expansion nationwide.
This momentum has carried over to LT350 gaining national and local attention as a common sense solution to the community resistance issues facing other data centers as evidenced by recent appearances on Fox Business News’ Varney & Co., Bloomberg News Network, Fox 17 Nashville, as well as multiple interviews with print outlets. This has accelerated the initiation of discussions with several strategic partners across fiber, real estate, enterprise, and hyperscaler ecosystems. These developments have materially increased both the clarity and magnitude of the LT350 opportunity underlying the merger.
2
2
302

